Analyst Consensus ?
ConsensusBuy49 ratings
Bullish3469.4%
Neutral1530.6%
Bearish00.0%
FN2 Earnings Intelligence
Regeneron Pharmaceuticals, Inc. analyst ratings
Regeneron Pharmaceuticals, Inc. (REGN) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$781.49Current
$584Low
$851.94Average
$1,292High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 12, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| HSBC | Buy | Buy | Maintain | Sep 10, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Aug 17, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 3, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Truist Securities | Buy | Buy | Maintain | Jul 31, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Jul 31, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 9, 2026 |
| Benchmark | Buy | Hold | Upgrade | Jul 7, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | May 19, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 18, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | May 18, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Apr 23, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Feb 2, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jan 22, 2026 |
| B of A Securities | Buy | Underperform | Upgrade | Jan 7, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Nov 24, 2025 |
| UBS | Neutral | Neutral | Maintain | Nov 7, 2025 |
| Jefferies | Buy | Buy | Maintain | Aug 27, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 30, 2025 |
| Baird | Neutral | Neutral | Maintain | Apr 30, 2025 |
| Argus Research | Buy | Buy | Maintain | Jun 25, 2024 |
| Raymond James | Outperform | Market Perform | Upgrade | Nov 3, 2023 |
| EF Hutton | Buy | Buy | Maintain | May 1, 2023 |
| SVB Leerink | Outperform | Market Perform | Upgrade | Mar 27, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jan 30, 2023 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Nov 5, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 23, 2021 |
| SunTrust Robinson Humphrey | Buy | Hold | Upgrade | Jul 9, 2020 |
| CFRA | Hold | Hold | Maintain | May 27, 2020 |
| Argus | Hold | Buy | Downgrade | Jun 18, 2019 |
| Leerink Swann | Outperform | Outperform | Maintain | Feb 9, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Feb 9, 2018 |
| BTIG | Neutral | Buy | Downgrade | Feb 9, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 13, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 13, 2017 |
| Chardan Capital | Neutral | Sell | Upgrade | Dec 12, 2016 |
| Roth Capital | Buy | Buy | Maintain | Apr 4, 2016 |
| Gabelli & Co. | Buy | Buy | Maintain | Mar 15, 2016 |
| Brean Capital | Buy | Buy | Maintain | Feb 10, 2016 |
| Bank of America | Buy | Buy | Maintain | Nov 21, 2014 |
| Argus Capital | Buy | Buy | Maintain | Jul 21, 2014 |
| Lazard | Buy | Buy | Maintain | Sep 13, 2013 |
| JMP Securities | Perform | Market Perform | Maintain | Mar 28, 2013 |
| Bank oferica | Buy | Buy | Maintain | May 29, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $781.49. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| HSBC | Rajesh Kumar | $920 | $807.65 | +17.7% | Sep 10, 2026 |
| Leerink Partners | David Risinger | $824 | $803.48 | +5.4% | Aug 17, 2026 |
| Bernstein | Jeffrey Walch | $756 | $799.46 | -3.3% | Aug 14, 2026 |
| Guggenheim | Analyst unavailable | $1,030 | $763.51 | +31.8% | Aug 3, 2026 |
| RBC Capital | Analyst unavailable | $737 | $739.5 | -5.7% | Jul 31, 2026 |
| Morgan Stanley | Analyst unavailable | $758 | $738.82 | -3.0% | Jul 31, 2026 |
| Cantor Fitzgerald | Carter Gould | $795 | $742.59 | +1.7% | Jul 31, 2026 |
| Robert W. Baird | Analyst unavailable | $761 | $738.34 | -2.6% | Jul 31, 2026 |
| Wells Fargo | Analyst unavailable | $750 | $738.34 | -4.0% | Jul 31, 2026 |
| Guggenheim | Yatin Suneja | $1,000 | $675.72 | +28.0% | Jul 21, 2026 |
| Piper Sandler | Biren Amin | $854 | $662.88 | +9.3% | Jul 9, 2026 |
| Morgan Stanley | Terence Flynn | $730 | $676.23 | -6.6% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $769 | $670.54 | -1.6% | Jul 7, 2026 |
| HSBC | Analyst unavailable | $800 | $643 | +2.4% | Jul 6, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $750 | $654.27 | -4.0% | Jul 6, 2026 |
| Canaccord Genuity | John Newman | $875 | $629.68 | +12.0% | May 19, 2026 |
| Wolfe Research | Alexandria Hammond | $860 | $629.36 | +10.0% | May 18, 2026 |
| Evercore ISI | Analyst unavailable | $825 | $619.84 | +5.6% | May 18, 2026 |
| RBC Capital | Analyst unavailable | $707 | $619.62 | -9.5% | May 18, 2026 |
| Truist Financial | Analyst unavailable | $778 | $619.95 | -0.4% | May 18, 2026 |
| BMO Capital | Analyst unavailable | $730 | $698.25 | -6.6% | May 18, 2026 |
| Piper Sandler | Analyst unavailable | $855 | $698.25 | +9.4% | May 18, 2026 |
| Leerink Partners | Market Perform | $641 | $698.25 | -18.0% | May 18, 2026 |
| Guggenheim | Yatin Suneja | $995 | $707.06 | +27.3% | May 1, 2026 |
| Morgan Stanley | Terence Flynn | $788 | $703.18 | +0.8% | Apr 30, 2026 |
| Truist Financial | Analyst unavailable | $796 | $692.75 | +1.9% | Apr 30, 2026 |
| Barclays | Analyst unavailable | $917 | $686.36 | +17.3% | Apr 30, 2026 |
| Raymond James | Chris Raymond | $910 | $746.58 | +16.4% | Apr 22, 2026 |
| Morgan Stanley | Analyst unavailable | $796 | $746.15 | +1.9% | Apr 10, 2026 |
| Bernstein | Analyst unavailable | $921 | $775.53 | +17.9% | Apr 8, 2026 |
| Truist Financial | Greg Renza | $818 | $770.32 | +4.7% | Mar 9, 2026 |
| Barclays | Eliana Merle | $923 | $764.93 | +18.1% | Mar 6, 2026 |
| RBC Capital | Brian Abrahams | $765 | $784.06 | -2.1% | Mar 2, 2026 |
| Guggenheim | Analyst unavailable | $975 | $785.51 | +24.8% | Feb 9, 2026 |
| Cantor Fitzgerald | Carter Gould | $800 | $757.59 | +2.4% | Feb 2, 2026 |
| Robert W. Baird | Brian Skorney | $742 | $755.34 | -5.1% | Feb 2, 2026 |
| Oppenheimer | Analyst unavailable | $865 | $741.45 | +10.7% | Feb 2, 2026 |
| Tudor Pickering | William Pickering | $925 | $753.13 | +18.4% | Feb 2, 2026 |
| Morgan Stanley | Terence Flynn | $769 | $741.45 | -1.6% | Feb 1, 2026 |
| Raymond James | Analyst unavailable | $870 | $741.45 | +11.3% | Jan 30, 2026 |
| Tudor Pickering | William Pickering | $916 | $762.1 | +17.2% | Jan 27, 2026 |
| RBC Capital | Brian Abrahams | $745 | $769.05 | -4.7% | Jan 27, 2026 |
| Bernstein | Analyst unavailable | $916 | $762.65 | +17.2% | Jan 27, 2026 |
| Evercore ISI | Analyst unavailable | $875 | $761.56 | +12.0% | Jan 22, 2026 |
| Goldman Sachs | Analyst unavailable | $914 | $812.27 | +17.0% | Jan 8, 2026 |
| Leerink Partners | Andrew Berens | $873 | $746.36 | +11.7% | Dec 17, 2025 |
| Morgan Stanley | Terence Flynn | $768 | $741.52 | -1.7% | Dec 12, 2025 |
| HSBC | Analyst unavailable | $985 | $692.58 | +26.0% | Dec 10, 2025 |
| BMO Capital | Evan Seigerman | $850 | $723.67 | +8.8% | Dec 4, 2025 |
| Canaccord Genuity | Analyst unavailable | $1,057 | $723.67 | +35.3% | Dec 4, 2025 |
| Truist Financial | Analyst unavailable | $798 | $766.5 | +2.1% | Nov 24, 2025 |
| Scotiabank | Analyst unavailable | $770 | $769.23 | -1.5% | Nov 24, 2025 |
| HSBC | Analyst unavailable | $890 | $755.9 | +13.9% | Nov 24, 2025 |
| Wells Fargo | Mohit Bansal | $700 | $702.75 | -10.4% | Nov 20, 2025 |
| RBC Capital | Analyst unavailable | $708 | $653.01 | -9.4% | Oct 29, 2025 |
| Cantor Fitzgerald | Carter Gould | $740 | $657 | -5.3% | Oct 29, 2025 |
| BMO Capital | Evan Seigerman | $725 | $654.48 | -7.2% | Oct 29, 2025 |
| Wells Fargo | Analyst unavailable | $615 | $654.48 | -21.3% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $637 | $645.93 | -18.5% | Oct 29, 2025 |
| Bernstein | Analyst unavailable | $818 | $654.42 | +4.7% | Oct 29, 2025 |
| Guggenheim | Analyst unavailable | $865 | $654.48 | +10.7% | Oct 29, 2025 |
| Robert W. Baird | Brian Skorney | $630 | $654.48 | -19.4% | Oct 29, 2025 |
| Raymond James | Christopher Raymond | $723 | $654.48 | -7.5% | Oct 28, 2025 |
| Morgan Stanley | Analyst unavailable | $767 | $654.48 | -1.9% | Oct 28, 2025 |
| Morgan Stanley | Analyst unavailable | $756 | $568.81 | -3.3% | Oct 10, 2025 |
| Raymond James | Christopher Raymond | $673 | $577.9 | -13.9% | Sep 2, 2025 |
| BMO Capital | Analyst unavailable | $640 | $571.54 | -18.1% | Aug 4, 2025 |
| Wells Fargo | Mohit Bansal | $580 | $563.43 | -25.8% | Aug 1, 2025 |
| UBS | Trung Huynh | $584 | $559.76 | -25.3% | Jul 11, 2025 |
| Morgan Stanley | Terence Flynn | $754 | $560.28 | -3.5% | Jul 10, 2025 |
| Morgan Stanley | Terence Flynn | $755 | $490.81 | -3.4% | Jun 2, 2025 |
| Cantor Fitzgerald | Carter Gould | $695 | $585.49 | -11.1% | Apr 22, 2025 |
| Canaccord Genuity | John Newman | $850 | $585.49 | +8.8% | Apr 22, 2025 |
| BMO Capital | Analyst unavailable | $903 | $666.87 | +15.5% | Mar 14, 2025 |
| BMO Capital | Evan David Seigerman | $1,190 | $843.6 | +52.3% | Nov 1, 2024 |
| Piper Sandler | Christopher Raymond | $1,195 | $843.6 | +52.9% | Nov 1, 2024 |
| Leerink Partners | Andrew Berens | $880 | $843.6 | +12.6% | Nov 1, 2024 |
| Evercore ISI | Cory Kasimov | $1,170 | $838.2 | +49.7% | Oct 31, 2024 |
| Evercore ISI | Cory Kasimov | $1,175 | $941.39 | +50.4% | Oct 24, 2024 |
| Wells Fargo | Mohit Bansal | $1,050 | $962.34 | +34.4% | Oct 23, 2024 |
| Truist Financial | Thomas Klee | $1,200 | $1,091.98 | +53.6% | Sep 24, 2024 |
| Leerink Partners | David Risinger | $1,077 | $1,091.98 | +37.8% | Sep 24, 2024 |
| Robert W. Baird | Brian Skorney | $940 | $1,091.98 | +20.3% | Sep 24, 2024 |
| Goldman Sachs | Salveen Richter | $1,292 | $1,091.98 | +65.3% | Sep 24, 2024 |
| BMO Capital | Evan David Seigerman | $1,300 | $1,159.94 | +66.3% | Sep 12, 2024 |
| RBC Capital | Brian Abrahams | $1,282 | $1,139.41 | +64.0% | Sep 9, 2024 |
| Raymond James | Christopher Raymond | $1,242 | $1,187.66 | +58.9% | Aug 23, 2024 |
| Bank of America Securities | Geoff Meacham | $805 | $1,077.48 | +3.0% | Aug 2, 2024 |
| RBC Capital | Brian Abrahams | $1,240 | $1,093.14 | +58.7% | Aug 2, 2024 |
| Raymond James | Christopher Raymond | $1,166 | $1,063.6 | +49.2% | Jul 19, 2024 |
| Guggenheim | Yatin Suneja | $1,180 | $1,085.62 | +51.0% | Jul 18, 2024 |
| UBS | Trung Huynh | $1,250 | $1,092.31 | +60.0% | Jul 12, 2024 |
| Morgan Stanley | Terence Flynn | $1,182 | $1,071.12 | +51.2% | Jul 11, 2024 |
| Argus Research | Jasper Hellweg | $1,170 | $1,063.89 | +49.7% | Jun 25, 2024 |
| RBC Capital | Brian Abrahams | $1,299 | $1,022.03 | +66.2% | Jun 13, 2024 |
| RBC Capital | Brian Abrahams | $1,229 | $1,010.54 | +57.3% | Jun 12, 2024 |
| RBC Capital | Brian Abrahams | $1,200 | $998.64 | +53.6% | Jun 4, 2024 |
| BMO Capital | Evan David Seigerman | $1,082 | $992.47 | +38.5% | Jun 3, 2024 |
| Raymond James | Christopher Raymond | $1,000 | $982.29 | +28.0% | May 20, 2024 |
| Evercore ISI | Cory Kasimov | $1,150 | $976.96 | +47.2% | May 13, 2024 |
| RBC Capital | Brian Abrahams | $1,185 | $937.61 | +51.6% | May 3, 2024 |
| Jefferies | Akash Tewari | $1,060 | $911.78 | +35.6% | Apr 12, 2024 |
| RBC Capital | Brian Abrahams | $1,189 | $921.34 | +52.1% | Apr 11, 2024 |
| Morgan Stanley | Matthew Harrison | $1,115 | $965.47 | +42.7% | Mar 13, 2024 |
| BMO Capital | Brian Abrahams | $1,076 | $934.06 | +37.7% | Jan 12, 2024 |
| RBC Capital | Brian Abrahams | $1,076 | $933.2 | +37.7% | Jan 12, 2024 |
| Leerink Partners | Andrew Berens | $976 | $820 | +24.9% | Mar 27, 2023 |
| Jefferies | Akash Tewari | $925 | $819.68 | +18.4% | Mar 24, 2023 |
| EF Hutton | Analyst unavailable | $853 | $769.94 | +9.2% | Feb 8, 2023 |
| RBC Capital | Analyst unavailable | $787 | $786.94 | +0.7% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $883 | $783.13 | +13.0% | Feb 6, 2023 |
| Leerink Partners | Analyst unavailable | $834 | $783.13 | +6.7% | Feb 6, 2023 |
| Guggenheim | Analyst unavailable | $915 | $707.63 | +17.1% | Nov 11, 2022 |
| Goldman Sachs | Analyst unavailable | $970 | $726.93 | +24.1% | Oct 3, 2022 |
| Canaccord Genuity | Analyst unavailable | $750 | $710.21 | -4.0% | Sep 16, 2022 |
| Piper Sandler | Analyst unavailable | $775 | $701.15 | -0.8% | Sep 13, 2022 |
| Wells Fargo | Analyst unavailable | $800 | $718.82 | +2.4% | Sep 12, 2022 |
| Barclays | Analyst unavailable | $815 | $708.85 | +4.3% | Sep 9, 2022 |
| Morgan Stanley | Matthew Harrison | $851 | $708.85 | +8.9% | Sep 9, 2022 |
| Jefferies | Akash Tewari | $675 | $708.85 | -13.6% | Sep 8, 2022 |
| Morgan Stanley | Matthew Harrison | $625 | $628.71 | -20.0% | Aug 15, 2022 |
| BMO Capital | Analyst unavailable | $788 | $614.96 | +0.8% | Aug 4, 2022 |
| Morgan Stanley | Analyst unavailable | $619 | $604.3 | -20.8% | Jul 15, 2022 |
| RBC Capital | Kennen MacKay | $638 | $597.62 | -18.4% | Jun 29, 2022 |
| Wells Fargo | Mohit Bansal | $735 | $571.81 | -5.9% | Jun 11, 2022 |
| Morgan Stanley | Analyst unavailable | $610 | $626.94 | -21.9% | Jun 3, 2022 |
| Argus Research | Analyst unavailable | $760 | $683.02 | -2.7% | May 31, 2022 |
| Leerink Partners | Geoffrey Porges | $738 | $680.22 | -5.6% | May 23, 2022 |
| Credit Suisse | Lorenzo Biasio | $725 | $681.91 | -7.2% | May 23, 2022 |
| Morgan Stanley | Analyst unavailable | $620 | $638.13 | -20.7% | May 5, 2022 |
| Barclays | Carter Gould | $745 | $733.02 | -4.7% | Apr 16, 2022 |
| BMO Capital | Evan David Seigerman | $780 | $638.41 | -0.2% | Feb 13, 2022 |
| Barclays | Carter Gould | $700 | $622.36 | -10.4% | Feb 7, 2022 |
| RBC Capital | Kennen MacKay | $679 | $622.96 | -13.1% | Feb 4, 2022 |
| Cowen & Co. | Tyler Van Buren | $640 | $622.96 | -18.1% | Feb 4, 2022 |
| J.P. Morgan | Cory Kasimov | $604 | $622.96 | -22.7% | Feb 4, 2022 |
| Evercore ISI | Joshua Schimmer | $680 | $622.85 | -13.0% | Feb 2, 2022 |
| Morgan Stanley | Matthew Harrison | $585 | $611.22 | -25.1% | Jan 18, 2022 |
| Bernstein | Aaron Gal | $660 | $627.1 | -15.5% | Jan 3, 2022 |
| Goldman Sachs | Salveen Richter | $824 | $625 | +5.4% | Dec 6, 2021 |
| Cantor Fitzgerald | Alethia Young | $760 | $622.2 | -2.7% | Nov 10, 2021 |
| UBS | Esther Rajavelu | $763 | $646.11 | -2.4% | Sep 9, 2021 |
| Argus Research | Jasper Hellweg | $590 | $528.75 | -24.5% | Jun 14, 2021 |
| Canaccord Genuity | John Newman | $700 | $506.72 | -10.4% | May 21, 2021 |
Track every rating change on REGN the moment it posts. Free to start.
Start free